Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (10): 1002-1009.doi: 10.19982/j.issn.1000-6621.20220205
• Original Article • Previous Articles Next Articles
An Huiru, Han Yiran, Yan Mengdie, Wu Xueqiong()
Received:
2022-05-30
Online:
2022-10-10
Published:
2022-09-30
Contact:
Wu Xueqiong
E-mail:xueqiongwu@139.com
Supported by:
CLC Number:
An Huiru, Han Yiran, Yan Mengdie, Wu Xueqiong. Meta-analysis on clinical effectiveness of combination regimens with interferon-γ in treatment of pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2022, 44(10): 1002-1009. doi: 10.19982/j.issn.1000-6621.20220205
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220205
第一作者 | 发表 年份 | 患者例数 | 男∶女 | 平均年龄(岁) | 病例特点 | 抗结核药物治疗方案 | 治疗组IFN-γ用法 | 结局指标 |
---|---|---|---|---|---|---|---|---|
对照组/ 观察组 | 对照组/ 观察组 | 对照组/观察组 | 剂量频次,途径,疗程 | |||||
刘建德[ | 1999 | 60/60 | NA/NA | NA/NA | 初复治,老年 | 3H-R-Z-S/6H-R-Z | 100WIU/2次/w,im,3m | ②④⑥ |
梁伟成[ | 2003 | 35/36 | 21:14/21:15 | 42.0/39.5 | 复治菌阳 | 2H3R3Z3E3S3/6H3R3E3 | 100WIU/次/2d, ih或im,2m | ①②③⑥ |
要玉霞[ | 2003 | 34/32 | 23:11/22:10 | NA/NA | 耐多药 | 3D-Z-E-Lfx-Am/6D-E-Lfx | 100WIU/2次/d,3次/w,inh,3m | ①②⑤⑥ |
阳光辉[ | 2005 | 20/25 | NA/NA | NA/NA | 耐多药 | 3Z-Pto-Lfx-E-Am/4Z-Pto-Lfx | 200WIU/次/2d,im,3m | ①②④ |
徐俊彦[ | 2006 | 20/23 | 12:8/16:7 | 48.0±12.0/45.0±11.0 | 耐多药 | 3Am-D-Pto-Lfx-L2/15D-Pto-Lfx-L2 | 500WIU/3次/w,inh,3m | ①③⑦ |
王琳[ | 2006 | 73/63 | 46:32/38:25 | 49.6±6.2/47.7±3.5 | 初治菌阳 | 2H-R-Z-S/4H-R(E) | 100WIU/次/2d,im,2m | ①②③④ |
王守京[ | 2007 | 64/64 | 44:20/44:20 | NA/NA | 复治菌阳 | 12D-L2-Pto-Z-Lfx | 100WIU/3次/w,im,6m | ②④⑥ |
林存智[ | 2007 | 28/36 | NA/NA | NA/NA | 多耐药 | 2H-R-Z-E(S)/6H-R-E | 100W0WIU/次/d, inh,2m | ③④ |
李丹[ | 2008 | 40/40 | NA/NA | NA/NA | 初治菌阳 | 2H-R-Z-E/4H-R | 100WIU/次/2d,im,2m | ①③ |
施军卫[ | 2008 | 11/11 | NA/NA | NA/NA | 耐多药 | 3H-PAS-E-Z-Am-Lfx/9Z-E-Lfx | 200WIU/3次/w,inh,6m | ②④⑦⑧⑨⑩ |
林存智[ | 2008 | 38/38 | 24:14/26:12 | 44.7±3.8/48.5±5.2 | 耐多药 | 3H-R-Z-E(S)/6H-R-E | 100WIU/次/2d,inh,2m | ④ |
张彦秋[ | 2009 | 35/35 | NA/NA | 48.0±17.0/52.0±13.0 | 复治菌阳 | 2D-L3-Pto-Z-Lfx | 500μg/3次/w,inh,2m | ①③④⑤ |
杨之怡[ | 2009 | 30/30 | NA/NA | NA/NA | 耐多药 | 3Sp-D-Z-E-Pto/9Sp-D-E | NA, inh,2m | ①⑦ |
李炳杰[ | 2011 | 30/30 | NA/NA | NA/NA | 耐多药 | 3D-L3-Pto-Z-Lfx | 100WIU/3次/w, ih,3m | ①③⑤ |
范凌[ | 2017 | 40/40 | 24:16/24:16 | 54.6±4.8/53.5±4.3 | 耐药 | 3H-R-Z-E | 3WIU/3次/w,inh,6m | ①②③④⑦⑧⑨⑩ |
胡丽娜[ | 2019 | 41/41 | 25:16/24:17 | 37.7±6.29/38.1±7.0 | 耐多药 | 3E-Pto-Z-Lfx-Am | 100μg/3次/w, inh,3m | ①⑤⑦⑩ |
李杨[ | 2019 | 15/15 | 8:7/9:6 | 34.3±2.2/35.2±2.1 | 耐药 | 2H-R-Z-E-S/6H-R-E | 300WIU/3次/w,inh,6m | ①②④ |
胡丽娜[ | 2019 | 54/54 | 34:20/32:32 | 53.7±4.4/54.1±4.4 | 耐药 | 6H-L2-Z-E | 300WIU/3次/w, inh,6m | ①②⑧⑨ |
[1] |
Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4):10.1128/microbiolspec.GPP3-0022-2018. doi: 10.1128/microbiolspec.GPP3-0022-2018.
doi: 10.1128/microbiolspec.GPP3-0022-2018 |
[2] |
中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识. 中国防痨杂志, 2022, 44(1):9-27. doi: 10.19982/j.issn.1000-6621.20210680.
doi: 10.19982/j.issn.1000-6621.20210680 |
[3] |
Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systema-tic review. Int J Infect Dis, 2011, 15(9):e594-600. doi: 10.1016/j.ijid.2011.05.002.
doi: 10.1016/j.ijid.2011.05.002 URL |
[4] |
Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet, 1997, 349(9064):1513-1515. doi: 10.1016/S0140-6736(96)12273-X.
doi: 10.1016/S0140-6736(96)12273-X pmid: 9167461 |
[5] |
Suárez-Méndez R, García-García I, Fernández-Olivera N, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis, 2004, 4:44. doi: 10.1186/1471-2334-4-44.
doi: 10.1186/1471-2334-4-44 pmid: 15500691 |
[6] |
Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci, 2004, 19(2):167-171. doi: 10.3346/jkms.2004.19.2.167.
doi: 10.3346/jkms.2004.19.2.167 URL |
[7] |
Park SK, Cho S, Lee IH, et al. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis, 2007, 11(5):434-440. doi: 10.1016/j.ijid.2006.12.004.
doi: 10.1016/j.ijid.2006.12.004 URL |
[8] |
Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One, 2009, 4(9):e6984. doi: 10.1371/journal.pone.0006984.
doi: 10.1371/journal.pone.0006984 URL |
[9] | 刘建德, 金海珠. 应用抗结核药物并干扰素治疗老年肺结核60例分析. 黑龙江医药科学, 1999, 22(4):68. |
[10] | 梁伟成. 干扰素γ对复治菌阳肺结核辅助治疗的临床观察. 中国临床医药研究杂志, 2003, 101:3-5. |
[11] | 要玉霞, 刘传玉. 干扰素辅助治疗耐多药结核病的疗效观察. 中国防痨杂志, 2003, 25(1):43-44. |
[12] |
阳光辉. α-干扰素辅助治疗耐药性肺结核的近期疗效观察. 广西医学, 2005, 27(8):1276-1277. doi: 10.3969/j.issn.0253-4304.2005.08.110.
doi: 10.3969/j.issn.0253-4304.2005.08.110 |
[13] | 徐俊彦. 干扰素-γ辅助治疗耐多药结核疗效观察. 中国临床医药研究杂志, 2006, 152:34. |
[14] | 王琳, 汪学智, 程秋兰, 等. 肌注重组IFN-γ联合抗结核药治疗肺结核的效果. 中国防痨杂志, 2006, 28(2):77-79. |
[15] |
王守京. γ干扰素辅助治疗复治肺结核近期疗效观察. 中国误诊学杂志, 2007, 7(19):4505-4506. doi: 10.3969/j.issn.1009-6647.2007.19.049.
doi: 10.3969/j.issn.1009-6647.2007.19.049 |
[16] | 林存智, 朱新红, 张海燕, 等. 干扰素-γ雾化吸入治疗初治涂阳和复治多耐药肺结核病的临床研究. 全国复治肺结核诊断与治疗进展研讨会, 2006:102-105. |
[17] | 李丹, 杜德兵, 邱绍勤, 等. γ-干扰素联合微卡对初治菌阳肺结核的早期疗效及细胞免疫功能的影响. 中国防痨杂志, 2008, 30(5):460-462. |
[18] |
施军卫, 袁瑛, 顾红艳. γ-干扰素雾化吸入联合治疗11例耐多药肺结核的临床疗效对比分析. 临床肺科杂志, 2008, 13 (12):1653-1654. doi: 10.3969/j.issn.1009-6663.2008.12.063.
doi: 10.3969/j.issn.1009-6663.2008.12.063 |
[19] |
林存智, 朱新红, 张海燕, 等. 重组人干扰素-γ治疗复治耐多药肺结核的临床免疫学研究. 中国医师进修杂志, 2008, 31(1):21-23. doi: 10.3969/j.issn.1009-6663.2008.12.063.
doi: 10.3969/j.issn.1009-6663.2008.12.063 |
[20] |
张彦秋, 何昌武, 李海泉, 等. γ-干扰素雾化气溶胶辅助治疗复治菌阳肺结核疗效观察. 医学综述, 2009, 15(2):306-307. doi: 10.3969/j.issn.1006-2084.2009.02.050.
doi: 10.3969/j.issn.1006-2084.2009.02.050 |
[21] | 杨之怡, 王琳, 郭立人, 等. 重组人γ-干扰素雾化吸入辅助治疗耐多药结核病的近期疗效观察. 中国防痨杂志, 2009, 31(11):660-663. |
[22] |
李炳杰. γ-干扰素对耐多药结核病的干预. 中国现代药物应用, 2011, 5(4):143-144. doi: 10.3969/j.issn.1673-9523.2011.04.125.
doi: 10.3969/j.issn.1673-9523.2011.04.125 |
[23] |
范凌, 纪风兵, 周琴. 干扰素联合化疗对耐药肺结核临床症状及免疫功能的影响. 西部医学, 2017, 29(6):817-820,825. doi: 10.3969/j.issn.1672-3511.2017.06.018.
doi: 10.3969/j.issn.1672-3511.2017.06.018 |
[24] | 胡丽娜. γ-干扰素辅助治疗对耐多药肺结核患者免疫功能及痰菌阴转率的影响. 临床研究, 2019, 27(5):60-62. |
[25] |
李杨. γ-干扰素联合化疗对耐药肺结核治疗效果. 医学信息, 2019, 32(z2):150-151. doi: 10.3969/j.issn.1006-1959.2019.z2.147.
doi: 10.3969/j.issn.1006-1959.2019.z2.147 |
[26] |
胡丽娜. γ-干扰素联合化疗对耐药肺结核治疗效果及患者免疫功能的影响. 北方药学, 2019, 16(4):29-30. doi: 10.3969/j.issn.1672-8351.2019.04.021.
doi: 10.3969/j.issn.1672-8351.2019.04.021 |
[27] |
Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev, 2011, 240(1):235-251. doi: 10.1111/j.1600-065X.2010.00994.x.
doi: 10.1111/j.1600-065X.2010.00994.x pmid: 21349097 |
[28] |
王科, 杨帆, 罗平, 等. 重组人γ-干扰素辅助治疗脊柱结核手术的临床研究. 现代生物医学进展, 2014, 14 (17):3322-3324. doi: 10.13241/j.cnki.pmb.2014.17.032.
doi: 10.13241/j.cnki.pmb.2014.17.032 |
[1] | National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879. |
[2] | Ultrasound Professional Committee of Tuberculosis Branch of Chinese Medical Association, Interventional Ultrasound Professional Committee of Interventional Physician Branch of Chinese Medical Doctor Association Danwei. Expert consensus on ultrasound diagnosis, classification and interventional therapy of tuberculous pleurisy (2022 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 880-897. |
[3] | Bao Rong, Gao Jianfeng, Rao Yan. Pathological types and characteristics of experimental pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 898-905. |
[4] | Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910. |
[5] | Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916. |
[6] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
[7] | Wang Ni, Huang Fei, Zhu Limei, Zeng Yi, Zhang Ruimei, Geng Hong, Liu Xuefa, Zheng Jiangang, Zong Peilan, Zeng Zhong, Li Jinlan, Cai Cui, Guo Xiaohong, Zhong Yin, Liu Li, Xie Yan, Du Fangfang, Zhou Lin, Cheng Shiming. Implementation study on promoting the use of anti-tuberculosis fixed-dose combination in provincial and prefecture tuberculosis designated hospitals [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 927-933. |
[8] | Wei Ganhui, Zhang Jiacheng, Qiu Xiaowei. Application value of volume CT value inquantifying the activity of pulmonary tuberculosis lesions above 5 mm [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 934-939. |
[9] | Wang Chaohong, Sun Qing, Liao Xinlei, Yan Jun, Wang Chenqian, Jiang Guanglu, Wang Fen, Xue Yi, Huang Hairong, Wang Guirong. Analysis of drug resistance situation of Mycobacterium tuberculosis strains from 231 spinal tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 940-946. |
[10] | Nie Tingyue, Chen Wei, Zhang Jieying, Cao Hong, Qian Bing, Gu Yingqiang, Liu Xuxiang. Analysis of spatial distribution characteristics of pulmonary tuberculosis cases in Hefei City, 2009—2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 947-953. |
[11] | Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959. |
[12] | Chen Qiuqi, Han Tingting, Wang Qingwen, Deng Guofang. Recent advances in treatment of latent tuberculosis infection complicated with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 960-965. |
[13] | Han Xu, Guan Shangqi, Shi Yinpeng, Mei Yifang. The risk of tuberculosis infection with non-tumor necrosis factor-targeted drugs in the treatment of rheumatoid arthritis [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 966-972. |
[14] | Yao Rong, Lu Yu. Research progress on the drug resistance and mechanism of the anti-tuberculosis drug bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 973-977. |
[15] | Xie Fanghui, Liang Li, Zhao Xia, Yao Rong, Lei Limei, Guo Hui, Meng Meng, Wan Bin. Research progress of sputum specimen collection in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 978-982. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||